Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo

International Journal of Cancer

Volumn 124, Issue 5, 2009, Pages 1227-1234

  Palmberg, Ebba ^a   Johnsen, John Inge ^a   Paulsson, Janna ^a   Gleissman, Helena ^a   Wickström, Malin ^b   Edgren, Margareta ^a   Östman, Arne ^a   Kogmer, Per ^a   Lindskog, Magnus ^a,b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IMATINIB; IRINOTECAN; MELPHALAN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL EXPANSION; CELL PROLIFERATION; CLINICAL FEATURE; CLONOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; MALE; MONOTHERAPY; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SHORT COURSE THERAPY; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEUROBLASTOMA; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 58749099283     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24069     Document Type: Article

References (53)

1. Brodeur GM, Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Maris JM, Hogarty MD. Bagatell R. Colin SL. Neuroblastoma. Lancet 2007;269:2106-20.
3. Moen MD, McKeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid leukemia. Drugs 2007;67:299-320.
4. Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R, Dominici C. Antitumor activity of imatinib mesylate in neuroblastoma xenografts, Cancer Lett 2005;228:211-9.
5. Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Per-ennon C, Freneaux P, Livartowski A, Pouillart P, Poupon MF. In vivo efficacy of STT571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005; 113:849-56.
6. Kilic T, Alberta JA, Zdunek PR, Acar M, lannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopy rimidine class. Cancer Res 2000;60:5143-50.
7. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-6.
8. Heldin CH, Westermark B Signal transduction by the receptors for platelet-derived growth factor. J Cell Sci 1990;96 (Pt 2); 193-6,
9. Claesson-Welsh L, Eriksson A, Moren A, Severinsson L, Ek B, Ostman A, Betsholtz C, Heldin CH. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B- chain-containing PDGF molecules. Mol Cell Biol 1988;8:3476-86.
10. Richardson WD, Pringle N, Mosley MJ, Westermark B, Dubois-Dalcq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell 1988;53:309-19.
11. Pahlman S, Johansson I, Westermark B, Nister M, Platelet-derived growth factor potentiates phorbol ester-induced neuronal differentiation of human neuroblastoma cells. Cell Growth Differ 1992;3:783-90.
12. Kaneko M, Yang W, Matsumoto Y, Watt F, Funa K. Activity of a novel PDGF beta-receptor enhancer during the cell cycle and upon differentiation of neuroblastoma. Exp Cell Res 2006;312:2028-39.
13. Gllbertson RJ. Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003;35:197-8.
14. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Hirael-stein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900-8.
15. Romashkova JA. Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature 1999;401:86-90.
16. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992;80:374-81.
17. Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwig WD, Zsebo K, Welte K. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992;80:1199-206.
18. Timeus F, Crescenzio N, Valle P, Pistamiglio P, Piglione M, Garelli E, Ricotti E, Rocchi P, Strippoli P, Cordero di Montezemolo L, Madon E, Ramenghi U, et al. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol 1997;25:1253-60.
19. Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H, Naka-mura H, Chihara K, Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest 1993;92:1153-60.
20. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group, Blood 1994;84:3465-72.
21. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Man-narino O, Natali PG, Raschella G, Dominici C. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 2003; 106:147-52.
22. Shimada A, Hirato J, Kuroiwa M, Kikuchi A, Hanada R, Wakai K, Hayashi Y, Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr Blood Cancer 2008;50: 213-7.
23. Sveinbjörnsson B, Rasrauson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A, Haeggström JZ, Johnsen JI, Kogner P. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy, FASEB J 2008;22:3525-36.
24. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 2006; 118:2584-93.
25. Puck TT, Marcus PI, Cieciura SJ. Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single HeLa cells with and without a feeder layer, J Exp Med 1956; 103:273-83.
26. Larsson R, Nygren P, Ekberg M, Slater L, Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiauto-mated fluorometric assay. Leukemia 1990;4:567-71.
27. Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafs-son MG, Isaksson A, Larsson R. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006;58:749-58.
28. Ponthan F, Johnsen JI, Klevenvall L, Castro J, Kogner P. The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo. Int J Cancer 2003;104:418-24.
29. Beppu K. Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression, J Natl Cancer Inst 2004;96:46-55.
30. Ponthan F, Wickström M, Gleissman H, Fuskevag OM, Segerström , Sveinbjön B, Redfern CP, Eksborg S, Kogner P, Johnsen JI. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007;13:1036-44.
31. Rebbaa A, Chou PM, Emran M, Mirk in BL, Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria. Cancer Chemother Pharmacol 2001;48:423-8.
32. Fulda S, Susin SA, Kroemer G, Debatin KM, Molecular ordering of apoptosis induced by anticancer drugs In neuroblastoma ceils. Cancer Res 1998;58:4453-60.
33. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 2006:208:220-8.
34. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial. Lancet Oncol 2008;9:247-56.
35. Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Roso-len A, Ricotti E, Basso G. Imatinib mesylate (STT571) interference with growth of neuroectodermal tumor cell lines does not critically involve c-Kit inhibition. Int J Mol Med 2004;14:373-82.
36. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M. Imatinib mesylate (STT571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children's oncology group phase 1 study. Blood 2004;104:2655-60.
37. Bond M, Bernstein ML, Pappo A, Sehultz KR, Krailo M, Blaney SM, Adamson PC, A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008;50:254-8.
38. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006:81:1241-57,
39. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15:275-86.
40. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillarv transport In tumors. Cancer Res 2001 ;61:2929-34.
41. Tewey KM, Rowe TC, Yang L, Hialligan BD, Liu LF, Adriamycin-induced DNA damage mediated by mammalian DNA topisomerase II, Science 1984;226:466-68.
42. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1,
43. Bruce TA, Slevin NJ, Homer JJ, McGown AT, Ward TH. Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 2005;16:719-26.
44. McDowell HP, Meco D, Riccardi A, Tanno B, Berardi AC, Raschellà G, Riccardi R, Dominici C. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. Int J Cancer 2006;120:1141-9.
45. Ogawa Y, Kawamura T, Furuhashi M, Tsukamoto K, Shimada S. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate J Dermatol Sci 2008;51:190-9.
46. Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts, Clin Cancer Res 2008; 14:541-8.
47. Uccini S, Mannarino O, McDowell HP, Pauser U, Vitali R, Natali PG, Altavista P, Andreano T, Coco S, Boldrini R, Bosco S, Clerico A, et al. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res 2005; 11:380-9.
48. Cattaneo MG, Scita G, Vicentini LM. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells. FEBS Lett 1999;459:64-8.
49. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited bv specific cytokines. EMBO J 1994;13:3286-95.
50. Funa K, Ahgren A. Characterization of platelet-derived growth factor (PDGF) action on a mouse neuroblastoma cell line, NB41, by introduction of an antisense PDGF beta-receptor RNA. Cell Growth Differ 1997;8:861-9.
51. Bourgeade MF, Defachelles AS, Cayre YE, Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta), Blood 1998;91:3333-9.
52. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat3-medi-ated Myc expression is required for Src transformation and PDGF-induced mitogenesis, Proc Natl Acad Sci USA 2001;98:7319-24.
53. Brondyk WH, Boeckman FA, Fahl WE. N-myc oncogene enhances mitogenic responsiveness of diploid human fibroblasts to growth factors but fails to immortalize. Oncogene 1991;6:1269-76.